Large-scale combination screens reveal small-molecule sensitization of antibiotic-resistant gram-negative ESKAPE pathogens
Open Access
- 24 March 2025
- journal article
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 122 (13)
Abstract
Antibiotic resistance, especially in multidrug-resistant ESKAPE pathogens, remains a worldwide problem. Combination antimicrobial therapies may be an important strategy to overcome resistance and broaden the spectrum of existing antibiotics. However, this strategy is limited by the ability to efficiently screen large combinatorial chemical spaces. Here, we deployed a high-throughput combinatorial screening platform, DropArray, to evaluate the interactions of over 30,000 compounds with up to 22 antibiotics and 6 strains of gram-negative ESKAPE pathogens, totaling to over 1.3 million unique strain-antibiotic-compound combinations. In this dataset, compounds more frequently exhibited synergy with known antibiotics than single-agent activity. We identified a compound, P2-56, and developed a more potent analog, P2-56-3, which potentiated rifampin (RIF) against antibiotic-resistant strains of Acinetobacter baumannii and Klebsiella pneumoniae . Using phenotypic assays, we showed P2-56-3 disrupts the outer membrane of A. baumannii . To identify pathways involved in the mechanism of synergy between P2-56-3 and RIF, we performed genetic screens in A. baumannii . CRISPRi-induced partial depletion of lipooligosaccharide transport genes ( lptA - D , lptFG ) resulted in hypersensitivity to P2-56-3/RIF treatment, demonstrating the genetic dependency of P2-56-3 activity and RIF sensitization on lpt genes in A. baumannii. Consistent with outer membrane homeostasis being an important determinant of P2-56-3/RIF tolerance, knockout of maintenance of lipid asymmetry complex genes and overexpression of certain resistance-nodulation-division efflux pumps—a phenotype associated with multidrug-resistance—resulted in hypersensitivity to P2-56-3. These findings demonstrate the immense scale of phenotypic antibiotic combination screens using DropArray and the potential for such approaches to discover new small molecule synergies against multidrug-resistant ESKAPE strains.Keywords
Funding Information
- HHS | NIH | National Institute of Allergy and Infectious Diseases (U19AI42780)
- HHS | NIH | National Institute of Allergy and Infectious Diseases (R01AI169789)
- HHS | NIH | National Institute of Allergy and Infectious Diseases (T32AI007422)
- HHS | NIH | National Institute of Allergy and Infectious Diseases (U19AI158076)
- HHS | NIH | National Institute of Allergy and Infectious Diseases (1U01AI124302-01)
- HHS | NIH | National Institute of Allergy and Infectious Diseases (R21AI128328-02)
This publication has 64 references indexed in Scilit:
- New potentiators of ineffective antibiotics: Targeting the Gram-negative outer membrane to overcome intrinsic resistanceCurrent Opinion in Chemical Biology, 2022
- Global burden of bacterial antimicrobial resistance in 2019: a systematic analysisThe Lancet, 2022
- Mismatch-CRISPRi Reveals the Co-varying Expression-Fitness Relationships of Essential Genes in Escherichia coli and Bacillus subtilisCell Systems, 2020
- A Deep Learning Approach to Antibiotic DiscoveryCell, 2020
- Lipopolysaccharide biogenesis and transport at the outer membrane of Gram-negative bacteriaBiochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2017
- Synthesis of Complex and Diverse Compounds through Ring Distortion of Abietic AcidAngewandte Chemie, 2013
- Pseudomonas aeruginosa: all roads lead to resistanceTrends in Microbiology, 2011
- A Planning Strategy for Diversity‐Oriented SynthesisAngewandte Chemie International Edition, 2003
- Trimethoprim-Sulfamethoxazole RevisitedArchives of internal medicine (1960), 2003
- Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings 1PII of original article: S0169-409X(96)00423-1. The article was originally published in Advanced Drug Delivery Reviews 23 (1997) 3–25. 1Advanced Drug Delivery Reviews, 2001